Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators... see more

TSX:QIPT - Post Discussion

Quipt Home Medical Corp > management said they were sticking to their guidance
View:
Post by gibbonsj on Dec 14, 2022 11:56am

management said they were sticking to their guidance

Of 200 million year end 2022 correct? Not sure if it was actually 200 million. I'm sure one of you will know.
Comment by LionGate7 on Dec 14, 2022 12:49pm
Reiteration of Outlook for Calendar End 2022 (Fiscal Q1 2023) Based on the current operations, market trends and completed and prospective acquisitions, the Company is reiterating it outlook for its annual run-rate revenue by the end of calendar 2022 (Fiscal Q1 2023) to be $180-$190 million with $38-$43 million in run-rate Adjusted EBITDA.  I would expect news early next week before the ...more  
Comment by LionGate7 on Jan 04, 2023 9:01pm
I was expecting a medium to large acquisition by year end and Quipt delivered in style with a better than expected transformative acquisition of Great Elm Healthcare. Greg and his team have delivered as promised, with an effective date of December 31, 2022 with the purchase of a company with $60 million in annual revenues. What a great way to start 2023! I'm expecting 2023 to be a big year for ...more  
Comment by lscfa on Dec 14, 2022 12:56pm
Market is forward looking. Even if yearend 2022 target is missed by a bit, co. is going to announce a 2023 year end target which will be considerably higher.   
Comment by gibbonsj on Dec 14, 2022 1:16pm
Not like management to overstate expectations. Do you think 2023 will be the year of the transformational acquisition?
Comment by Tropicalsun on Dec 14, 2022 1:44pm
Speaking with the company IR person a few weeks back, he said that Quipt still expects to meet their forecasted revenue run rate of 180 to 190 million by the end of Calender 2022. I believe they sit right now in the neighborhood of 165 million, so without news of an acquisition of pretty good size, how do they meet the target? Is it a big deal if they don't hit the target? I think from a ...more  
Comment by Carlito3311 on Dec 14, 2022 6:34pm
This post has been removed in accordance with Community Policy
Comment by lscfa on Dec 14, 2022 3:48pm
p.s. Co. might up its ebitda margin for 2023 revenues due to inflation increase to reimbursement rates which drops straight to ebitda and net income.
Comment by lscfa on Dec 14, 2022 4:09pm
"As of July, we had reached approximately $160 million in run-rate revenue and are well on our way to meeting our outlook." organic growth of 2.5% for each of  Sept qtr and Dec qtr => 160 x1.025 x1.025 = $168 million
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities